Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas J Ball

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Journal of Toxicology|August 15, 2020
Permitted Daily Exposure Values: Application Considerations in Toxicological Risk AssessmentsDouglas J Ball, William P Beierschmitt
PDA Journal of Pharmaceutical Science and Technology|February 19, 2015
Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: A Literature ReviewDennis R Jenke, Cheryl L M Stults, Diane M Paskiet, et al.
Regulatory Toxicology and Pharmacology : RTP|February 18, 2018
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responsesMark Collinge, Douglas J Ball, Christopher J Bowman, et al.
Toxicologic Pathology|October 2, 2008
N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studiesDaniel Morton, Keith L Bailey, Cheryl L Stout, et al.
Regulatory Toxicology and Pharmacology : RTP|October 28, 2017
Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma developmentZaher A Radi, W Mark Vogel, Phillip M Bartholomew, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 7, 2016
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig CellsRobert E Chapin, Douglas J Ball, Zaher A Radi, et al.
Regulatory Toxicology and Pharmacology : RTP|August 30, 2016
Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics - Current challenges and approachesThomas H Broschard, Susanne Glowienke, Uma S Bruen, et al.
Transplantation|December 27, 2005
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primatesDominic C Borie, Michael J Larson, Mona G Flores, et al.
Science (New York, N.Y.)|November 1, 2003
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitorPaul S Changelian, Mark E Flanagan, Douglas J Ball, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Toxicology|August 15, 2020
Permitted Daily Exposure Values: Application Considerations in Toxicological Risk AssessmentsDouglas J Ball, William P Beierschmitt
PDA Journal of Pharmaceutical Science and Technology|February 19, 2015
Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: A Literature ReviewDennis R Jenke, Cheryl L M Stults, Diane M Paskiet, et al.
Regulatory Toxicology and Pharmacology : RTP|February 18, 2018
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responsesMark Collinge, Douglas J Ball, Christopher J Bowman, et al.
Toxicologic Pathology|October 2, 2008
N-Methyl-N-Nitrosourea (MNU): A positive control chemical for p53+/- mouse carcinogenicity studiesDaniel Morton, Keith L Bailey, Cheryl L Stout, et al.
Regulatory Toxicology and Pharmacology : RTP|October 28, 2017
Cellular and functional actions of tofacitinib related to the pathophysiology of hibernoma developmentZaher A Radi, W Mark Vogel, Phillip M Bartholomew, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 7, 2016
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig CellsRobert E Chapin, Douglas J Ball, Zaher A Radi, et al.
Regulatory Toxicology and Pharmacology : RTP|August 30, 2016
Assessing safety of extractables from materials and leachables in pharmaceuticals and biologics - Current challenges and approachesThomas H Broschard, Susanne Glowienke, Uma S Bruen, et al.
Transplantation|December 27, 2005
Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primatesDominic C Borie, Michael J Larson, Mona G Flores, et al.
Science (New York, N.Y.)|November 1, 2003
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitorPaul S Changelian, Mark E Flanagan, Douglas J Ball, et al.
Pageof 1